Hemolytic anemia historical perspective

Jump to navigation Jump to search

Hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI Scan

Echocardiography or Ultrasound

Imaging Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic anemia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic anemia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic anemia historical perspective

CDC on Hemolytic anemia historical perspective

Hemolytic anemia historical perspective in the news

Blogs on Hemolytic anemia historical perspective

Directions to Hospitals Treating Hemolytic anemia

Risk calculators and risk factors for Hemolytic anemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Historical Perspective

  • In 1891, Paul Ehrlich discovered that methylene blue had activity against malaria.[1]
  • In 1920, it was noted that primaquine was an effective anti-malarial medication.
  • In 1953, there was large-scale use of primaquine for troops in the army in order to protect against malaria, and it was soon noted that soldiers developed abdominal discomfort, anemia, and jaundice.[1]
  • In 1956, Carson's group showed that people who experienced hemolysis from primaquine had decreased level of G6PD.[1]
  • In 1962, Alving's group showed that acute hemolytic anemia could be triggered by primaquine.[1]

References

  1. 1.0 1.1 1.2 1.3 Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.

Template:WS Template:WH